{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:07:29Z","timestamp":1778897249096,"version":"3.51.4"},"reference-count":31,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To explore whether the vancomycin plus piperacillin\/tazobactam (VPT) combination increased risk of acute kidney injury (AKI) compared to vancomycin plus cefepime (VC) in a cohort of Hispanic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center, retrospective study. Adult Hispanic patients receiving at least 48\u2005hours of concomitant vancomycin and \u03b2-lactam therapy were included. Patients were excluded if they had documented allergies to study antibiotics, had antibiotics indicated for a central nervous system infection, were pregnant, had cystic fibrosis, a malignancy, or a creatinine clearance level of 30\u2005mL\/min or less, or had preexisting AKI within 48\u2005hours before initiation of antibiotics. The primary outcome was the incidence of AKI, defined by a rise in serum creatinine level as described in KDIGO guidelines. A subgroup analysis was performed to assess AKI incidence with stratification into 3 vancomycin area under the curve (AUC) ranges: 400-499\u2005mg \u00b7 h\/L, 500-599\u2005mg \u00b7 h\/L, and \u2265600\u2005mg \u00b7 h\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 89 patients were included in the study: 45 in the VPT group and 44 in the VC group. AKI occurred in 23 of the patients receiving VPT (51%) compared to 10 of the patients receiving VC (23%) (odds ratio [OR], 2.25; 95% confidence interval [CI], 1.22-4.16; P = 0.006). For the subgroup analysis, a significant difference was seen in AKI between VPT and VC in the subgroup with a vancomycin AUC of 400-499\u2005mg \u00b7 h\/L (OR, 0.303; 95% CI, 0.102-0.897; P = 0.035).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that there might be higher risk of AKI with VPT in the Hispanic population. Further studies are needed to confirm these findings and to investigate potential ethnicity-specific susceptibility to kidney injury associated with vancomycin combination therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag127","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:43:07Z","timestamp":1776944587000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of acute kidney injury incidence in Hispanic patients receiving empiric vancomycin and piperacillin\/tazobactam versus vancomycin and cefepime"],"prefix":"10.1093","author":[{"given":"Gabriela","family":"Garcia Villa","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Sciences, The University of Texas at El Paso School of Pharmacy , El Paso, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University Medical Center at El Paso , El Paso, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaa K","family":"Abdelhakiem","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Clinical Sciences, The University of Texas at El Paso School of Pharmacy , El Paso, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"2026051521120424700_zxag127-B1","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"582","key":"2026051521120424700_zxag127-B2","doi-asserted-by":"crossref","first-page":"eabd6299","DOI":"10.1126\/scitranslmed.abd6299","article-title":"Mechanism and reversal of drug-induced nephrotoxicity on a chip","volume":"13","author":"Cohen","year":"2021","journal-title":"Sci Transl Med"},{"issue":"11","key":"2026051521120424700_zxag127-B3","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1016\/j.ekir.2023.07.037","article-title":"Clinical characteristics and outcomes of drug-induced acute kidney injury cases","volume":"8","author":"Yousif","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"7","key":"2026051521120424700_zxag127-B4","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/phar.1442","article-title":"Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam","volume":"34","author":"Burgess","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2026051521120424700_zxag127-B5","doi-asserted-by":"publisher","first-page":"106234","DOI":"10.1016\/j.ijantimicag.2020.106234","article-title":"Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury","volume":"57","author":"Muklewicz","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2026051521120424700_zxag127-B6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CCM.0000000000002769","article-title":"Vancomycin plus piperacillin-tazobactam and acute kidney injury in adults: a systematic review and meta-analysis","volume":"46","author":"Luther","year":"2018","journal-title":"Crit Care Med"},{"issue":"8","key":"2026051521120424700_zxag127-B7","doi-asserted-by":"publisher","first-page":"e0004022","DOI":"10.1128\/aac.00040-22","article-title":"Retrospective cohort study of the incidence of acute kidney injury with vancomycin area under the curve-based dosing with concomitant piperacillin-tazobactam compared to meropenem or cefepime","volume":"66","author":"Kiley","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2026051521120424700_zxag127-B8","doi-asserted-by":"publisher","first-page":"e0108523","DOI":"10.1128\/aac.01085-23","article-title":"Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin\/tazobactam or cefepime and meropenem","volume":"68","author":"Mefford","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2026051521120424700_zxag127-B9","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/jac\/dkae410","article-title":"Vancomycin combined with piperacillin\/tazobactam increases the risk of acute kidney injury compared with vancomycin plus other anti-pseudomonal \u03b2-lactams: a systematic review and network meta-analysis","volume":"80","author":"Pan","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"2026051521120424700_zxag127-B10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1093\/cid\/ciy724","article-title":"Incidence of acute kidney injury among critically ill patients with brief empiric use of antipseudomonal \u03b2-lactams with vancomycin","volume":"68","author":"Schreier","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2026051521120424700_zxag127-B11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health-Syst Pharm"},{"issue":"7","key":"2026051521120424700_zxag127-B12","doi-asserted-by":"publisher","first-page":"e0373923","DOI":"10.1128\/spectrum.03739-23","article-title":"Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study","volume":"12","author":"Ishigo","year":"2024","journal-title":"Microbiol Spectr"},{"issue":"7","key":"2026051521120424700_zxag127-B13","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1681\/ASN.0000000000000134","article-title":"Representation of racial and ethnic minorities in nephrology clinical trials: a systematic review and meta-analysis","volume":"34","author":"Soomro","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026051521120424700_zxag127-B14","author":"Centers for Disease Control and Prevention"},{"issue":"2","key":"2026051521120424700_zxag127-B15","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41581-021-00501-8","article-title":"Health inequities and the inappropriate use of race in nephrology","volume":"18","author":"Eneanya","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"2026051521120424700_zxag127-B16","doi-asserted-by":"publisher","first-page":"e202682","DOI":"10.1001\/jamanetworkopen.2020.2682","article-title":"Association between early recovery of kidney function after acute kidney injury and long-term clinical outcomes","volume":"3","author":"Bhatraju","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026051521120424700_zxag127-B17","doi-asserted-by":"publisher","first-page":"e02089","DOI":"10.1128\/AAC.02089-16","article-title":"Nephrotoxicity during vancomycin therapy in combination with piperacillin-tazobactam or cefepime","volume":"61","author":"Rutter","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2026051521120424700_zxag127-B18","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.2147\/DDDT.S524370","article-title":"Acute kidney injury associated with the concomitant use of vancomycin and piperacillin-tazobactam","volume":"19","author":"Chen","year":"2025","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2026051521120424700_zxag127-B19","doi-asserted-by":"publisher","first-page":"dlad157","DOI":"10.1093\/jacamr\/dlad157","article-title":"Association of piperacillin and vancomycin exposure on acute kidney injury during combination therapy","volume":"6","author":"Venugopalan","year":"2024","journal-title":"JAC Antimicrob Resist"},{"issue":"2","key":"2026051521120424700_zxag127-B20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1053\/j.ajkd.2018.08.008","article-title":"Risk factors for recurrent acute kidney injury in a large population-based cohort","volume":"73","author":"Liu","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"19","key":"2026051521120424700_zxag127-B21","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.3390\/jcm11195822","article-title":"The effects of race on acute kidney injury","volume":"11","author":"Hassan","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"2026051521120424700_zxag127-B22","doi-asserted-by":"publisher","first-page":"e0224655","DOI":"10.1371\/journal.pone.0224655","article-title":"EPILAT-IRA study: a contribution to the understanding of the epidemiology of acute kidney injury in Latin America","volume":"14","author":"Lombardi","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"2026051521120424700_zxag127-B23","doi-asserted-by":"publisher","first-page":"2449573","DOI":"10.1080\/0886022X.2024.2449573","article-title":"Prevalence of acute kidney injury in Mexico; a systematic review and meta-analysis of pre-pandemic reports","volume":"47","author":"Zaragoza","year":"2025","journal-title":"Ren Fail"},{"issue":"2","key":"2026051521120424700_zxag127-B24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.chest.2023.05.009","article-title":"Does vancomycin-piperacillin-tazobactam cause pseudo-AKI, true nephrotoxicity, or both?","volume":"164","author":"C\u00f4t\u00e9","year":"2023","journal-title":"Chest"},{"issue":"3","key":"2026051521120424700_zxag127-B25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2026051521120424700_zxag127-B26","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/j.1875-9114.1997.tb03690.x","article-title":"Suspected acute interstitial nephritis induced by piperacillin-tazobactam","volume":"17","author":"Pill","year":"1997","journal-title":"Pharmacotherapy"},{"issue":"3","key":"2026051521120424700_zxag127-B27","doi-asserted-by":"publisher","first-page":"e1444","DOI":"10.1093\/cid\/ciac670","article-title":"Nephrotoxicity of vancomycin in combination with \u03b2-lactam agents: ceftolozane-tazobactam vs piperacillin-tazobactam","volume":"76","author":"Alosaimy","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2026051521120424700_zxag127-B28","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1016\/j.jiac.2021.07.017","article-title":"Risk factors for acute kidney injury in vancomycin and piperacillin\/tazobactam combination therapy: a retrospective study","volume":"27","author":"Yamashita","year":"2021","journal-title":"J Infect Chemother"},{"issue":"8","key":"2026051521120424700_zxag127-B29","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1080\/1120009X.2025.2456327","article-title":"Piperacillin\/tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem","volume":"37","author":"Obara","year":"2025","journal-title":"J Chemother"},{"issue":"1","key":"2026051521120424700_zxag127-B30","doi-asserted-by":"publisher","first-page":"106691","DOI":"10.1016\/j.ijantimicag.2022.106691","article-title":"Piperacillin\/tazobactam and risk of acute kidney injury in adults hospitalized with infection without vancomycin: a multi-centre real-world data analysis","volume":"61","author":"Su","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"16","key":"2026051521120424700_zxag127-B31","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag127\/68172196\/zxag127.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag127\/68172196\/zxag127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:12:08Z","timestamp":1778893928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag127\/8663697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":31,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag127","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"article-number":"zxag127"}}